Science and commerce are looking at psychedelic substances such as psilocybin, LSD, Ketamine and MDMA and to treat many of the same neurological disorders that cannabis does and so much more.
Silo Pharma is one the few biotech’s we have come across with university collaborations and patented technology for treatments with psilocybin!
Silo’s goal is to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization.
Opportunities to invest in companies developing new technologies usually come too late. They come to our attention after a significant catalyst has already moved the price significantly higher and we find ourselves wishing we’d have gotten in while the shares were cheap. SILO is a company with shares that are still affordable, and we’ve laid out the reasons that might change soon below.
SILO has assembled a team of scientific advisors to ensure they are looking at viable projects and they have the available capital to finance them through the full term of development.
It wasn’t that long ago that developing biopharma treatments with cannabis derivatives was theoretical, and start-ups were cheap to invest in. A lot of fortunes have been made in the cannabis sector since.
Merging traditional therapeutics with psychedelic research.
Recent Developments and News
On July 7, 2021, SILO announced they extended their agreement for experimental Rheumatoid Arthritis nanoparticle homing peptide. Eric Weisblum, Chairman and CEO of Silo Pharma stated, “The ability to deliver traditional therapeutics, psilocybin or other psychedelic drugs directly to targeted areas of the body with this technology could be revolutionary by increasing the efficacy of the treatment while reducing toxicity and the amount of medication needed.”
SILO has entered into a Scientific Research Agreement (SRA) with the University of California San Francisco (UCSF). This SRA, just negotiated in June 2021, will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain.
On October 19, 2020, SILO was approved for trading on the OTCQB Venture Market, an upgrade from the pink sheets. On May 25, 2021, the company announced that it has submitted its initial application to list on the NASDAQ Capital Market.
Also in May 2021, the company announced that its investigator led study using Psilocybin to treat Parkinson’s disease has been submitted for ethics board review in the Netherlands. Eric Weisblum, CEO of Silo Pharma stated, “We are pleased to have reached this milestone and look forward to sharing further information on this study with the scientific community and our shareholders.”
Let’s look at the programs that SILO is involved with:
Investigator Lead sponsored study with Maastricht University, which utilizes repeated low doses of LSD and Psilocybin effects on cognitive and emotional dysfunction in Parkinson’s disease and to understand its mechanism of action. The investigator is completing acquiring the substances for the study and will then finalize the documentation to submit to the Ethics committee.
Silo Pharma, Inc. enters into an Exclusive Option Agreement with the University of Maryland, Baltimore for patented Homing Peptides Targeting Rheumatoid Arthritis. “Joint-homing peptides for use in the investigation and treatment of arthritogenic processes” novel joint-homing peptides may be used to treat autoimmune diseases, including but not limited to Rheumatoid Arthritis.
Silo Pharma Licenses Novel Peptide-Guided Drug Delivery Approach for the Treatment of MS. An innovative Central nervous system-homing peptides for treatment of multiple sclerosis and other neuroinflammatory pathology, signing a Master License Agreement with the University of Maryland Baltimore.
Silo Pharma Entered into a Sponsored Research Agreement for Potential Multiple Sclerosis Treatment Approach with University of Maryland, Baltimore
Silo Pharma receives $1M in up front licensing deal for its Psilocybin cancer therapeutic applications. In consideration for granting the license, Silo Pharma received a one-time cash payment of $500,000 and shares of newly designated Convertible Preferred Stock valued at $500,000 on the date of execution of the license. Silo Pharma will also be entitled to potential royalty payments on Net Sales (as defined in the Agreement) if the licensed property is commercially developed.
Silo Pharma entered, completes, and grants a sub license agreement for the treatment of pain from neuroinflammation in cancer patients.
Silo Pharma (SILO) and Zylo Therapeutics, Inc. (ZTI) enter into Joint Venture Agreement to focus on the development of ketamine using ZTI’s Z-pod™ technology for the transdermal time released delivery of therapeutics.
With a current market value under $25M, SILO looks to be under the radar of a lot of biopharma investors. With an up-list to the NASDAQ pending SILO could quickly become well known and of course the market value could soar. A cursory look at development stage biopharma NASDAQ stocks will result in a plethora of companies valued in the hundreds of millions of dollars.
SILO already has collaborations with universities to develop leading edge science and innovative therapies for some of the hardest to treat indications. The combination of psychedelic compounds with existing and newly developed therapies is a novel approach to new treatments and SILO is at the forefront of these developments.
Let’s look at the SILO Intellectual Property portfolio:
U.S. Provisional Patent Application No. 63/060,573, titled “Central Nervous System Delivery of Psilocybin,” filed August 3, 2020.
U.S. Provisional Patent Application No. 63/060,569, titled “Central Nervous System Delivery of Nonsteroidal Anti-Inflammatory Drugs and Psilocybin,” filed August 3, 2020.
U.S. Provisional Patent Application No. 63/060,577, titled “Central Nervous System Delivery of Nonsteroidal Anti-Inflammatory Drugs and Psilocybin,” filed August 3, 2020.
U.S. Provisional Patent Application No. 63/24,827, titled “Use of Psilocybin in Cancer Treatment,” filed December 13, 2020.
The psychedelics sector is growing rapidly with many public companies already established and IPOs for others already planned. SILO happens to be several steps ahead of the pack with several patents pending, university collaborations and capital available for development. Its important to note that SILO is looking beyond depressive disorders and working to develop treatments for other indications.
Author and PhD, Joshua Cohen published an article on July 5, 2021, in Forbes titled “Psychedelic Drugs Are Moving from The Fringes of Medicine to the Mainstream”. His insights into the sector are invaluable and he discusses the FDA relationship with psychedelic compounds. It’s a great read for anyone with a current interest in this field of medicine.
SILO appears to be a value compared to its peers in the psychedelic sector (development stage, absent revenue):
Seelos Therapeutics, Inc. (SEEL) Market value – $270M
Mind Medicine Inc. (MNMD) Market value – $805M
COMPASS Pathways plc (CMPS) Market value – $1.5B
Silo Pharma, Inc. (SILO) Market value – $21M
Silo Pharma Inc’s CEO and Founder, Eric Weisblum, has over 25 years of Wall Street experience most recently in the biotechnology sector. Eric served on the board of directors of Aikido Pharma (AIKI), a Nasdaq-listed biotech company focused on the commercialization of oncology therapeutics where he advised on the operations and licensing of their technology. Prior to Aikido, he was the President of Sableridge Capital.
Do your due diligence on SILO and determine if you think the company shares might reward you handsomely in the future.
Silo Pharma, Inc.
Englewood Cliffs, NJ 07632
The Traders News Group and Lucky’s Breakout Stocks
Do we disclose any information to outside parties?
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.